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Abstract
Diabetes mellitus is a potentially morbid condition with high prevalence worldwide thus being a major medical
concern. Experimental induction of diabetes mellitus in animal models is essential for the advancement of our
knowledge and understanding of the various aspects of its pathogenesis and ultimately finding new therapies and
cure. Experimental diabetes mellitus is generally induced in laboratory animals by several methods that include:
chemical, surgical and genetic (immunological) manipulations. Most of the experiments in diabetes are carried out
in rodents, although some studies are still performed in larger animals. The present review highlights the various
methods of inducing diabetes in experimental animals in order to test the newer drugs for their anti-diabetic
potential.
Keywords: Streptozotocin, alloxan, diabetic rats, animal models, diabetes
Introduction
WHO reports Diabetes mellitus as one of the most
common public health problems which will affect a total
population of 220 million worldwide in the year 2020
[1,2]. The increasing prevalence of diabetes mellitus
worldwide is a major societal issue because diabetes is a
complex and multifactorial origin disease.
The prevalence of diabetes is rising all over the world
due to population growth, aging, urbanization and an
increase of obesity and physical inactivity. Unlike in the
West, where older persons are most affected, diabetes in
Asian countries is disproportionately high in young to
middle-aged adults. This could have long-lasting adverse
effects on a nation’s health and economy, especially for
developing countries. The International Diabetes Federa-
tion (IDF) estimates the total number of people in India
with diabetes to be around 50.8 million in 2010, rising
to 87.0 million by 2030.
According to recent estimates, approximately 285 mil-
lion people worldwide (6.6%) in the 20-79 year age
group will have diabetes in 2010 and by 2030, 438 mil-
lion people (7.8%) of the adult population, is expected
to have diabetes [3]. The largest increases will take place
in the regions dominated by developing economies.
According to the World Health Organization (WHO)
criteria, the prevalence of known diabetes was 5.6% and
2.7% among urban and rural areas, respectively [4].
Diabetes mellitus, often simply referred to as dia-
betes–is a group of metabolic diseases in which a person
has high blood sugar, either because the body does not
produce enough insulin, or because cells do not respond
to the insulin that is produced. This high blood sugar
produces the classical symptoms of polyuria (frequent
urination), polydipsia (increased thirst) and polyphagia
(increased hunger). Diabetes mellitus can be of different
types based on the cause of the disease.
Types of diabetes
There are three main types of diabetes which are briefly
described as below:
Type 1 diabetes
It results from the body’s failure to produce insulin, and
presently requires the person to inject insulin. (It is also
referred to as insulin-dependent diabetes mellitus,
IDDM for short, and juvenile diabetes). The majority of
type 1 diabetes is of the immune-mediated nature,
where beta cell loss is a T-cell mediated autoimmune
attack [5]. * Correspondence: pharm.vermasuresh@gmail.com
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It results from insulin resistance, a condition in which
cells fail to use insulin properly, sometimes combined
with an absolute insulin deficiency. It is also known as
non-insulin-dependent diabetes mellitus, NIDDM for
short, and adult-onset diabetes.
Gestational diabetes
This type of diabetes occurs in pregnant women, who
never had diabetes before, but have a high blood glucose
level during pregnancy. It may precede development of
type 2 diabetes mellitus [6].
Other diabetes
Other forms of diabetes mellitus include congenital dia-
betes, which is due to genetic defects of insulin secre-
tion, cystic fibrosis-related diabetes, steroid diabetes
induced by high doses of glucocorticoids, and several
forms of monogenic diabetes. Pre-diabetes indicate a
condition that occurs when a person’s blood glucose
levels are higher than normal but not high enough for a
diagnosis of type 2 diabetes. Many people destined to
develop type 2 diabetes spend many years in a state of
pre-diabetes which has been termed “America’sl a r g e s t
healthcare epidemic [7]. Latent autoimmune diabetes of
adults is a condition in which Type 1 diabetes develops
in adults. Adults with LADA are frequently initially mis-
diagnosed as having Type 2 diabetes, based on age
rather than etiology [8].
Genetic mutations (autosomal or mitochondrial) can
lead to defects in beta cell function. Abnormal insulin
action can be genetically determined in some cases. Any
disease that causes extensive damage to the pancreas
may lead to diabetes (for example chronic pancreatitis
and cystic fibrosis). Diseases associated with excessive
secretion of insulin antagonistic hormones can cause
diabetes (which is typically resolved once the hormone
excess is removed). Many drugs impair insulin secretion
and some toxins damage pancreatic beta cells [9].
Experimental induction of diabetes mellitus in animal
models is essential for the advancement of our knowl-
edge and understanding of the various aspects of its
pathogenesis and ultimately finding new therapies and
cure. Experimental studies in animals have the great
advantage to eliminate factors such as ethnicity, eco-
nomic and geographic variables, drug interactions, diet,
gender and age differences that importantly limit clinical
studies. Indeed, appropriate animal models have pro-
vided important informationo ng e n e t i ca n de n v i r o n -
mental risks of diabetes, and helped to dissect molecular
mechanisms underlying the development, progression
and therapeutic control of this disease [10]. Several
methods have been used to induce diabetes mellitus in
laboratory animals with variable success and many
difficulties. Surgical removal of the pancreas is an effec-
tive method, however, to induce diabetes, at least 90-
95% of the pancreas has to be removed [11].
The majority of studies published in the field of
ethno-pharmacology between 1996 and 2006 employed
chemical induced model. Streptozotocin (STZ) 69% and
alloxan 31% are by far the most frequently used drugs
and this model has been useful for the study of multiple
aspects of the disease [12]. Both drugs exert their diabe-
togenic action when they are administered parenterally
(intravenously, intraperitoneally or subcutaneously). The
dose of these agents required for inducing diabetes
depends on the animal species, route of administration
and nutritional status [13].
STZ (N-nitro derivative of glucosamine) is a naturally
occurring, broad spectrum antibiotic and cytotoxic che-
mical that is particularly toxic to the pancreatic, insulin
producing beta cells in mammals [14-17]. Induction of
experimental diabetes in the rat using STZ is very con-
venient and simple to use [18,19]. STZ injection leads to
the degeneration of the Langerhans islets beta cells
[20,21].
Alloxan, a well- known diabetogenic agent is widely
used to induce type 2 diabetes in animals [22]. The drug
and its reduction product dialuric acid establish a redox
cycle with the formation of superoxide radicals. These
radicals undergo dismutation to hydrogen peroxide.
Thereafter, highly reactive hydroxyl radicals are formed
by fenton reaction. The action of reactive oxygen species
with a simultaneous massive increase in cytosolic cal-
cium concentration causes rapid destruction of b cells
[23]. Alloxan induced diabetes mellitus serve as a patho-
logical biomodel for testing a substance with supposed
antioxidant activities in vivo [24]. One of the targets of
the reactive oxygen species is DNA of pancreatic islets.
Its fragmentation takes place in b cells exposed to
alloxan [25]. The increase in oxygen free radicals in dia-
betic conditions is mainly because of the effect of the
diabetogenic agent alloxan.
Although the use of chemical (alloxan and STZ) to
induce type 2 diabetes mellitus is the most widely used
method, recently it has been widely criticized as being
unsuitable because the chemical seems to destroy the b
cells and create more of type 1 than type 2 diabetes
[26].
Diagnosis of diabetes [27]
Different current diagnostic tests for diabetes mellitus
are,
(A) Measurement of blood glucose
The current WHO diagnostic criteria for diabetes are
measurement of blood glucose level. The fasting plasma
glucose greater than 7.0 mmol/l (126 mg/dl) or 2-h
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i n d i c a t et h a tt h ep e r s o nm a yh a v ed i a b e t e s .G l u c o s e
should be measured immediately after collection by near
patient testing, or if a blood sample is collected, plasma
should be immediately separated, or the sample should
be collected into a container with glycolytic inhibitors
and placed on ice-water until separated prior to analysis.
(B) Oral glucose tolerance test (OGTT)
OGTT is used as a diagnostic test as fasting plasma glu-
cose alone fails to diagnose approximately 30% of cases.
(C) Glycated Haemoglobin (HbA1c)
HbA1c can be used as a diagnostic test for diabetes pro-
viding that stringent quality assurance tests are in place
and assays are standardized to criteria aligned to the
international reference values, and there are no condi-
tions present which preclude its accurate measurement.
An HbA1c of 6.5% is recommended as the cut point for
diagnosing diabetes. A value of less than 6.5% does not
exclude diabetes diagnosed using glucose tests. Cur-
rently HbA1c is not considered a suitable diagnostic test
for diabetes or intermediate hyperglycemia [28].
(D) Fasting blood glucose test
Blood glucose levels are checked after fasting for
between 12 and 14 hours. Water can be taken during
this time, but should strictly avoid any other beverage.
Patients with diabetes may be asked to delay their dia-
betes medication or insulin dose until the test is com-
pleted [27].
(E) Random blood glucose test
Blood glucose levels are checked at various times during
the day, and it doesn’t matter the time of eating. Blood
glucose levels tend to stay constant in a person who
doesn’t have diabetes [27].
Cardiovascular complications associated with
diabetes
Several cardiovascular complications have been asso-
ciated with diabetes. These include Coronary Artery
Disease, Cerebral Vascular Disease, Peripheral Arterial
Disease, Stroke, TIAs, Heart Failure, Peripheral Arterial
Disease, High blood pressure etc. The relative risks for
total cardiovascular disease, coronary heart disease,
stroke, other cardiovascular disease, and all-cause mor-
tality increase two- to threefold in diabetic patients,
even after adjustment for several other known cardio-
vascular disease risk factors.
An association between overt diabetes and cardiovas-
cular disease has been observed in many studies [29,30].
In the developed world, the risk for cardiovascular dis-
ease has increased two- to four fold among diabetic
patients compared with non diabetic persons within
their corresponding population. Among persons with
NIDDM in the United States, up to 75% of deaths are
attributed to ischemic heart disease or other heart and
vascular disease [31]. Although the cardiovascular dis-
ease mortality rate has recently decreased in diabetic
p e r s o n sa sw e l la si nn o r m o g l y c e m i cp e r s o n s ,ah i g h e r
risk for cardiovascular disease remains a major problem
for diabetic patients [32].
Coronary Artery Disease
Coronary artery disease, also called ischemic heart dis-
ease, is caused by a hardening or thickening of the walls
of the blood vessels that go to your heart. Blood sup-
plies oxygen and other materials needed by heart for
normal functioning. If the blood vessels to heart are nar-
rowed or blocked by fatty deposits which normally is
reported to increase in a diabetic person the blood sup-
ply is reduced or cut off, resulting in a heart attack.
Cerebral Vascular Disease
Cerebral vascular disease affects blood flow to the brain,
leading to strokes and TIAs. It is caused by narrowing,
blocking, or hardening of the blood vessels that go to
the brain or by high blood pressure.
Peripheral Arterial Disease
Narrowing or blockage of the blood vessels in the legs, a
condition called peripheral arterial disease, can also
occur in people with diabetes.
Stroke
A stroke results when the blood supply to the brain is
suddenly cut off, which can occur when a blood vessel
in the brain or neck is blocked or the vessel bursts.
Brain cells are then deprived of oxygen and die. A
stroke can result in problems with speech or vision or
can cause weakness or paralysis. Most strokes are
caused by fatty deposits or blood clots jelly-like clumps
of blood cells that narrow or block one of the blood ves-
sels in the brain or neck. A blood clot may stay where it
formed or can travel within the body. People with dia-
betes are at increased risk for strokes caused by blood
clots. A stroke may also be caused by a bleeding blood
vessel in the brain. Called an aneurysm, a break in a
blood vessel can occur as a result of high blood pressure
or a weak spot in a blood vessel wall.
Transient Ischemic Attacks (TIAs)
TIAs are caused by a temporary blockage of a blood
vessel to the brain. This blockage leads to a brief, sud-
den change in brain function, such as temporary numb-
ness or weakness on one side of the body. Sudden
changes in brain function also can lead to loss of
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ble vision, difficulty speaking, or a severe headache.
However, most symptoms disappear quickly and perma-
nent damage is unlikely. If symptoms do not resolve in
a few minutes, rather than a TIA, the event could be a
stroke. The occurrence of a TIA means that a person is
at risk for a stroke sometime in the future.
Heart Failure
Heart failure is a chronic condition in which the heart
cannot pump blood properly. Heart failure develops over
a period of years, and symptoms can get worse over time.
People with diabetes have at least twice the risk of heart
failure as other people. Blockage of the blood vessels and
high blood glucose levels also can damage heart muscle
and cause irregular heartbeats. People damaged heart
muscle (a condition called cardiomyopathy) may have no
symptoms in the early stages, but later they may experi-
ence weakness, shortness of breath, a severe cough, fati-
gue, and swelling of the legs and feet. Diabetes can also
interfere with pain signals normally carried by the nerves,
explaining why a person with diabetes may not experi-
ence the typical warning signs of a heart attack.
Peripheral Arterial Disease
Another condition related to heart disease and common
in people with diabetes is peripheral arterial disease
(PAD). With this condition, the blood vessels in the legs
are narrowed or blocked by fatty deposits, decreasing
blood flow to the legs and feet. PAD increases the
chances of a heart attack or stroke occurring. Poor cir-
culation in the legs and feet also raises the risk of ampu-
tation. Sometimes people with PAD develop pain in the
calf or other parts of the leg when walking, which is
relieved by resting for a few minutes.
2. Experimental Models
Experimental diabetes mellitus is generally induced in
laboratory animals by several methods that include: che-
mical, surgical and genetic (immunological) manipula-
tions. Most of the experiments in diabetes are carried
out in rodents, although some studies are still per-
formed in larger animals.
The animal models employed for screening anti-dia-
betic agents can be broadly classified into three types
which are enlisted below [33].
A Methods to induce experimental diabetes mellitus
B Genetically diabetic animals
C Miscellaneous Models
A. Methods to induce experimental diabetes melli-
tus can be further sub-classified as under:-
a) Pancreatectomy in dogs
b) Alloxan induced diabetes
c) Streptozotocin induced diabetes
d) Hormone induced diabetes
e) Virus induced diabetes
f) Other diabetogenic compounds
g) Insulin deficiency due to insulin antibodies
B. Genetically diabetic animals can be further sub-
classified as under:
a) Spontaneously diabetic rats
b) Spontaneously diabetic mice
c) Chinese hamsters
d) Other species with inherited diabetic symptoms
e) Transgenic animals
C. Miscellaneous Models
a) Invertebrate animal model
b) Diet Induced metabolic dysregulation
Pancreatectomy in dogs
General Considerations
Polyuria, polydipsia, polyphagia, and severe glucosuria
take place after removal of the pancreas in dogs. The
reduction of the elevated blood sugar levels in pancrea-
tectomized dogs by injection of extracts of the pancrea-
tic glands further proved the existence of hormone in
pancreas [34]. The technique of complete pancreatect-
omy in the dog was first described in detail by Foà [35]
a n dt h e nb yS i r e k[ 3 6 ]a n dt h e r ea f t e rt h a ti th a sb e e n
extensively used by various scientists as an animal
model for diabetes mellitus
Method
Male Beagle dogs weighing 12-16 kg are anesthetized
with an intravenous injection of 50 mg/kg pentobarbital
sodium and placed on its back. A midline incision is
made from the xyphoid process reaching well below the
umbilicus. Bleeding vessels are ligated and the abdomen
is entered through the linea alba. The falciform ligament
is carefully removed and the vessels are ligated. A self-
retaining retractor is applied. By passing the right hand
along the stomach to the pylorus, the duodenum with
the head of the pancreas is brought into the operating
field. First, the mesentery at the unicate process is cut
and the process itself is dissected free. The glandular tis-
sue is peeled off from the inferior pancreatico-duodenal
artery and vein. The vessels themselves are carefully pre-
served along a line of cleavage which exists between the
pancreas, the pancreatico-duodenal vessels and the duo-
denal wall, the pancreas is separated from the duode-
num and from the carefully preserved pancreatico-
duodenal vessels. The small vessels to the pancreas are
ligated. The dissection is carried out from both sides of
the duodenum. In the area of the accessory pancreatic
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to be carefully removed in order to leave no residual
pancreatic tissue behind. The pancreatic duct is cleaned,
doubly ligated and cut between the ligatures. The dis-
section proceeds until one encounters a small lobe con-
taining the main pancreatic duct. The glandular tissue
adheres here firmly to the duodenum. Blunt dissection
and ligation of the vessels is followed by ligation of the
pancreatic duct. By pulling on the pylorus and the sto-
mach, the pyloric and the splenic parts of the pancreas
are delivered into the wound. The duodenal part is
placed back into the abdominal cavity. The mesentery of
the body and tail of the pancreas is cut with scissors.
The small vessels are doubly ligated and cut. The pan-
creatic tissue is bluntly dissected from the splenic ves-
sels. The pancreatic branches of the splenic vessels are
doubly ligated and cut. Working in direction from the
spleen to the pylorus, the pyloric part of the pancreas is
the last one to be dissected. Finally, all pancreatic tissue
is removed. The surgical field is checked once more for
pancreatic remnants. The concavity of the duodenum
and its mesentery is approximated by a few silk stitches
and the omentum is wrapped around the duodenum.
Retroperitoneal injection of 5 ml 1% procaine solution is
given to prevent intussusception of the gut. 250000 IU
penicillin G in saline solution is instilled into the perito-
neal cavity. The abdominal wall and the subcutaneous
layer are closed by sutures and finally the skin is sutured
with continuous everting mattress stitches. After the
operation, the animal receives via a jugular vein catheter
for 3-4 days the following treatment: 1000 ml 10% glu-
cose solution with 10 IU human insulin, 3 ml 24% sulfa-
dioxin/trimethoprim solution, 2 ml 50% metamizol and
400 IU secretin. On the third day, the animal is offered
milk. After the animal has passed the first milk feces, it
is given daily dry food together with a preparation of
pancreatic enzymes. Insulin is substituted with a single
daily subcutaneous dose of 34 IU Retard-Insulin. Vita-
min D3 is given every three months as a intramuscular
injection of 1 ml.
Alloxan induced diabetes
Objective
Surveys on chemically induced diabetes in animals were
given by Frerichs and Creutzfeldt [37]. Alloxan adminis-
tration cause hyperglycemia and glucosuria has been
described in several species, such as in dogs [38], in rab-
bits [39], in rats [40] and in other species [41]. Alloxan
resistance has been found in Guinea pig [42]. Dosage
and treatment regimen have been elaborated for the
most frequently used species. In most species a triphasic
time course is observed: an initial rise of glucose is fol-
lowed by a decrease, probably due to depletion of islets
from insulin, again followed by a sustained increase of
blood glucose. Alloxan generally produces greater cyto-
toxicity owing to its conversion to anionic radicals.
Method
Rabbits weighing 2.0 to 3.5 kg are infused with 150 mg/
kg alloxan monohydrate (5.0 g/100 ml, pH 4.5) through
ear vein for 10 min. This results in occurrence of hyper-
glycemia and uricosuria in 70% of the animals. The rest
of the animals either die or are only temporarily hyper-
glycemic [43]. Rats of Wistar or Sprague-Dawley strain
weighing 150-200 g are injected subcutaneously with
100-175 mg/kg alloxan [44]. Male Beagle dogs weighing
15-20 kg are injected intravenously with 60 mg/kg
alloxan. Subsequently, the animals receive daily 1 000
ml 5% glucose solution with 10 IU Regular insulin for
one week and canned food ad libitum. Thereafter, a sin-
gle daily dose of 28 IU insulin is administered subcuta-
neously [45]. The method was modified in which rats of
2, 4 and 6 days were injected with 200 mg/kg of alloxan
monohydrate after a 16 h fast [46].
Streptozotocin induced diabetes
Objective
Rakieten et al reported the diabetogenic activity of the
antibiotic Streptozotocin [47]. STZ is cytotoxic espe-
cially to beta- cells of the pancreas. Diabetes induction
in laboratory animals, mostly in rats, by STZ has
become a valuable tool in diabetes research being used
by many investigators. Parp-deficient mice are almost
resistant to STZ-induced diabetes [48].
Method
Male Wistar rats weighing 150-220 g are used. STZ (60
mg/kg) is injected intravenously. The serum insulin
values decrease up to 4 times, after six to eight hours of
injection, resulting in a hypoglycemic phase after persis-
tent hyperglycemia. Diabetic symptoms severity and
onset depend on the dose of STZ. After the dose of 60
mg/kg i.v., symptoms occur already after 24-48 h with
hyperglycemia up to 800 mg%, glucosuria and ketone-
mia. Histologically degranulation of the beta cells is
seen. After 10-14 days a steady state is reached allowing
using the animals for pharmacological tests.
Hormone induced diabetes
Growth hormone induced diabetes
T h ed i a b e t o g e n i ca c t i o no fp u r ea n t e r i o rp i t u i t a r y
growth hormone in cats has already been described [49].
The repeated administration of growth hormone in
adult dogs and cats induce intensive diabetes with all
symptoms including severe ketonuria and ketonemia
while rats do not show any sign of diabetes on a similar
treatment, but grow faster [50].
Corticosteroid induced diabetes
Cortisone can induce hyperglycemia and glucosuria in
treated rats [51]. In the guinea pig and in the rabbit,
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out forced feeding [52]. In the rat, the adrenal cortex,
stimulated by corticotrophin has the capacity to secrete
amounts of steroids which induce steroid diabetes [53].
Virus induced diabetes
Virus infections and beta-cell specific autoimmunity
may induce Juvenile-onset (type I) diabetes mellitus
[54]. Infection and destruction of pancreatic beta-cell by
D-variant of encephalomyocarditis virus (EMC-D)
induce diabetes [55]. Susceptibility to cause insulin-
dependent diabetes in mouse strains is similar to
human. Adult, male ICR Swiss mice are susceptible to
the diabetogenic effect of the D-variant of encephalo-
myocarditis virus present in ICR Swiss mice but C3H/
HeJ male mice are resistant. The severity and incidence
of diabetes is increased if the animals are pretreated
with cyclosporine (A potent immunosuppressive drug).
Other diabetogenic compounds
Objective
Symptoms of diabetes and obesity induction have been
found by several other compounds such as dithizone
[56] or goldthioglucose [57] or monosodium glutamate
[58]. Histopathology reveals complete or partial degra-
nulation of beta cells by the action of dithiazone.
Method
Goldberg et al used various chelators, such as dithizone,
8-(p-toluene-sulfonylamino)-quinoline (8-TSQ), and 8-
(benzenesulfanylamino)-quinoline for induction of dia-
betes in experimental animals [59]. Dithizone is injected
to cats, rabbits, golden hamsters and mice in a single i.v.
dose of 40-100 mg/kg. In rabbits dithizone injection
causes a triphasic glycemic reaction. After 2 h initial
hyperglycemia is detected followed by a normoglycemic
phase after 8 h and after 24-72 h a permanent
hyperglycemia.
Insulin deficiency due to insulin antibodies
Objective
Guinea pig anti-insulin serum can induce a transient
diabetic syndrome [60]. Guinea pig anti-insulin serum
i n d u c e su n i q u ee f f e c t .T h i si sd u et on e u t r a l i z a t i o nb y
insulin antibodies of endogenous insulin secreted by the
injected animal. This induces a state of insulin defi-
ciency. Ketonemia, ketonuria, glucosuria, and acidosis
are induced by larger dose. The diabetic syndrome is
reversible at lower doses after a few hours.
Method
Male guinea pigs weighing 300-400 g are used. 1 mg
dose of Bovine insulin is injected subcutaneously in
divided dose. Injections are given at monthly intervals.
10 ml blood from every animal once a month is with-
drawn by cardiac puncture. 0.25-1.0 ml guinea pig anti-
insulin serum is injected i.v. to rats. Anti-insulin serum
induces a dose-dependent increase in blood glucose up
to 300 mg%.
Genetically diabetic animals
General considerations
Rodents have been described to exhibit spontaneous dia-
betes mellitus on a hereditary basis. Since the discovery
of leptin [61] and its downstream signal transduction
cascade [62], new insight of the genetics of diabetic and
obese animal disease models were derived. Many geneti-
cally diabetic animal models exhibit defects in the leptin
pathway, various mutations in the mouse resulted in
leptin deficiency. Biologically inactive carboxipeptidase E
are formed as a result of fat mutation in the mouse,
which processes the prohormone conversion of POMC
into a-MSH, and activates the hypothalamic MC4
receptor. Ubiquitous expression of the Agouti protein
was exhibited by yellow mouse, which represents an
antagonist of the hypothalamic MC4 receptor. Symp-
toms of diabetes and obesity are overlapping in many
animal models
Critical assessment
The pathophysiological mechanisms which finally lead
to the diabetes phenotype (hyperglycemia, hyperinsuli-
nemia and insulin resistance) exhibited by the various
animal disease models for non-insulin dependent dia-
betes do not necessarily be identical to those in human
disease. Therefore, detailed knowledge about the patho-
physiology of these animal disease models is a prerequi-
site for interpretation of experimental results and their
value for the human disease.
Spontaneously diabetic rats
In several strains of rats occurrence of spontaneous dia-
betes has been reported:
Bio Breeding (BB) Rat
The BB rat is a model of spontaneous diabetes [63]. It is
associated with insulin deficiency and insulitis due to
autoimmune destruction of pancreatic beta cells. The
onset of clinical diabetes generally occurs at 60-120 days
of age. Severe hyperglycemia persists after several days
associated with hypoinsulinemia and ketosis. Immuno-
suppressive agent mycophenolate mofetil can prevent
the development of diabetes in BB rats [64]. The fea-
tures of a subline of diabetes-prone BB rats were charac-
terized by Kloting and Vogt [65].
WBN/KOB rat
These animals of Wistar strain, named as WBN/Kob rat
exhibit impaired glucose tolerance and glucosuria at 21
weeks of age. Decrease in the number and size of islets
after 12 weeks of age is observed. Yagihashi observed
fibrinous exudation and degeneration of pancreatic
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degeneration takes place mainly around islets and pan-
creatic ducts. These rats develop demyelination, predo-
minantly motor neuropathy.
Cohen diabetic rat
Cohen described that hyperglycemia, glucosuria and
hyperinsulinemia are characteristics of Cohen rats [67].
Late development of hypoinsulinemia, insulin resistance
and a decrease in the number and sensitivity of insulin
receptors in Cohen rats is observed. Diabetes related
complications are develop in rats when fed a diet rich in
sucrose or other refined sugars, but not when fed a
starch or stock diet [68].
Goto-Kakizaki (GK) rat
GK rats are non-obese, insulin-resistant. GK rats are
highly inherited strain of Wistar rats that spontaneously
develop type II diabetes. 2 to 4 weeks after birth defects
in glucose stimulated insulin secretion, peripheral insu-
lin resistance, and hyperinsulinemia are seen along with
impaired skeletal muscle glycogen synthase activation by
insulin. It is accompanied by chronic activation of dia-
cylglycerol-sensitive protein kinase C [69].
Zucker-fatty rat
Zucker described a classic model of hyperinsulinemic
obesity. Obesity occurs due to a simple autosomal reces-
sive (fa) gene at an early age [70]. Obese rats manifest
peripheral insulin resistance similar to human NIDDM
[71]. However, throughout life their blood sugar level is
usually normal.
Zucker diabetic fatty rat (ZDF/DRT-FA)
Peterson derived the obese Zucker Diabetic Fatty rat
originally from the Zucker fatty rat. This strain suffers
with hyperglycemia about 20 mmol/l [72]. The males
and females of 6 to 8 weeks and 9 to 11 weeks become
diabetic respectively. Lee described that lipotoxicity to
the b-cell is the cause of diabetes [73]. Extreme hyper-
phagia due to the loss of calories by glucosuria and obe-
sity besides hyperglycemia are the characteristics of
these animals.
WDF/TA-FA rat
Wistar fatty rats are genetically obese, hyperglycemic.
Velasquez et al. developed Wistar Kyoto rat by the
transfer of the fatty (fa)g e n ef r o mt h eZ u c k e rr a t[ 7 4 ] .
The Wistar fatty rat exhibits obesity, hyperinsulinemia,
hyperlipidemia, and hyperphagia, however they are more
insulin resistant. In females hyperglycemia is not
observed usually but it can be induced by addition of
sucrose to the diet.
OLETF rat
In 1984 diabetic rat with polyuria, polydipsia, and mild
obesity was discovered in an out bred colony of Long-
Evans rats. A strain of rats was developed from this rat
by selective breeding. Characteristic features of OLETF
rats are: (1) hyperglycemia onset is late (after 18 weeks
of age), (2) a chronic course of disease, (3) mild obesity,
(4) inheritance by males, (5) hyperplastic foci of pan-
creatic islets, and (6) renal complications (nodular
lesions). Human NIDDM features resemble with the
clinical and pathological features of disease in OLETF
rats. Aizawa et al. (1995) found that OLETF rats from
the age of 4 to 12 weeks completely prevented the
development of obesity and insulin resistance when
diazoxide (0.2% in diet), an inhibitor of insulin secretion
is administred. Insulin resistance preceded impaired
insulin secretion in OLETF rats [75].
ESS-rat
Tarrés et al reported that the occurrence of spontaneous
diabetes in a colony of rats (Stilman Saldago), called
them as ESS-rat [76]. From the age of 2 months
onwards the animals show abnormal glucose tolerance
tests. The syndrome consists of a mild type of diabetes
that does not diminish the longevity of the animals.
Dumm et al. showed the disruption of the islet architec-
ture and fibrosis of the stroma in six months old rats
[77].
OBESE SHR rat
Koletsky developed the strain of obese SHR rats [78].
This strain is produced by mating a spontaneous hyper-
tensive female rat of the Kyoto-Wistar strain with a nor-
motensive Sprague- Dawley male. Substrains such as the
JCRLA-corpulent rat were developed from these rats.
Russell et al described that these rats exhibits a syn-
drome characterized by obesity, hypertriglyceridemia
and hyperinsulinemia [79]. Friedman et al found in the
obese spontaneously hypertensive Koletsky rat that the
insulin receptor signaling was reduced [80].
SHR/N-CP rat
Adamo et al developed the congenic SHR/N-cp rat
strain at the National Institutes of Health, USA [81].
This strain was derived by mating a male Koletsky rat
heterozygous for the corpulent gene (cp/+) to a female
rat of the Okamoto strain. These rats exhibit obesity,
mild hypertension, hyperinsulinemia, and glucose
intolerance.
BHE rat
The BHE rat colony was originally developed by breed-
ing black and white hooded rats of the Pennsylvania
State College strain and albino rats of the Yale (Osborne
Mendell) strain. The BHE rats exhibited the diabetic
state only at maturity. These rats have hyperinsulinemia
at 50 days of age. Hyperglycemia is associated with glu-
cose intolerance and tissue resistance to insulin [82].
Spontaneously diabetic mice
KK mouse
Nakamura reported a diabetic strain of the KK-mouse.
The animals were moderately obese and showed poly-
phagia and polyuria [83]. Mice at the age of seven
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levels up to 320 mg%. The pancreatic insulin content
was increased, but histologically degranulation of the
beta-cells and hypertrophy of the islets were found. Sec-
tions of the liver showed a reduction of glycogen and an
increase in lipid content.
KK-AY mouse
Iwatsuka et al reported the mice carrying the yellow
obese gene (Ay) [84]. In these mice blood glucose and
circulating insulin levels as well as HbA1c levels are
increased progressively from 5 weeks of age. Degranula-
tion and glycogen infiltration of beta-cells and lipogen-
esis by liver and adipose tissue were increased. Diani et
al reported that the renal involvement is uniquely
marked by early onset and rapid development of glo-
merular basement membrane thickening [85]. The
extrapancreatic action of antidiabetic drugs, such as gli-
mepiride, a novel sulfonylurea can be demonstrated by
using KK-Ay mice.
NOD mouse
This strain was established by inbreeding diabetic CTS
mice derived originally from the JCLICR strain. The
NOD mouse is a model of insulin dependent diabetes
mellitus and develops hypoinsulinemia secondary to
autoimmune destruction of pancreatic b cells. Between
100 to 200 days of age NOD mice develop diabetes. The
NOD mouse does not survive for more than one month
if insulin treatment is not given. They usually die from
ketosis. Baeder et al, reported that an immunomodulat-
ing drug [86] or a soluble interleukin-1 receptor [87]
use can prevent the onset of diabetes. Verdaguer et al
observed that the insulin-dependent diabetes mellitus in
NOD mice is the result of a CD4+ and CD8+ T cell-
dependent auto-immune process directed against the
pancreatic b-cells [88].
OBESE hyperglycemic mice
Bleisch et al observed hereditary diabetes in genetically
obese mice. These mice are glycosuric, the non-fasting
blood sugar levels are about 300 mg%, but neither keto-
nuria nor coma is observed [89]. One of the most inter-
esting features is insulin resistance. The islands of
Langerhans are hypertrophic, their insulin content is
increased. No pathological changes shown in kidneys
and other organs. Obviously, the diabetic condition of
the human diabetic patient is different from that of
obese hyperglycemic mice. Halaas et al, reported the
substitution of leptin reverses the obese and diabetic
phenotype completely [90]. Herberg and Coleman
described the other strains or substrains of mice with
obesity and hyperglycemia [91].
Diabetes mouse (DB/DB)
Autosomal recessive mutation derived diabetes in db/db
mouse strain is spontaneously diabetic mice which was
identified as a mutation in the leptin receptor gene [92].
As e v e r ed i a b e t i cs y n d r o m ei sd e v e l o p e di nt h em i c e
characterized by early onset of hyperinsulinemia, and
hyperglycemia [93]. They also developed significant
nephropathy. Mutations on the leptin receptor result in
an obese phenotype identical to that of ob mice.
C57BL/KsJ ob/ob mice are phenotypically the same as
other strains of db mice. The leptin receptor (Ob-R)
gene encodes 5 alternatively spliced forms, Ob-Ra, Ob-
Rb, Ob-Rc, Ob-Rd. In the C57BL/KsJ ob/ob mouse
strain, the Ob-Rb transcript contains an insert with a
premature stop codon as a result if abnormal splicing
[94].
Diabetes obesity syndrome in CBA/CA mice
Male CBA/Ca mice have a spontaneous maturity onset
diabetes obesity syndrome that occurs in a small pro-
portion (10-20%). The incidence can increase upto 80%
after inbreeding. It occurs at 12-16 weeks of age. Dia-
betic obesity syndrome is characterized by hyperphagia,
obesity, hyperglycemia, hypertriglyceridemia and hyper-
insulinemia. Exogenous insulin is resistant to mice.
Female mice remains normal except for a slight increase
in serum insulin [95].
Wellesley mouse
Jones described the Wellesley mouse. This mouse is a
hybrid with predisposition to diabetes mellitus [96]. Like
and Jones reported that the diabetic animals have ele-
vated levels of immunoreactive insulin in serum,
enlarged pancreatic islets and reduced insulin respon-
siveness in peripheral tissues [97].
Chinese hamster
The occurrence of hereditary diabetes mellitus in the
Chinese hamster (Cricetulus griseus) is described by
Meier and Yerganian [98]. Diabetic hamsters have ele-
vated blood sugar levels ranging from a normal of 110
mg% up to 600 mg%. Diabetic symptoms observed in
Chinese hamsters are severe polyuria, glucosuria, keto-
nuria, and proteinuria. Administration of insulin, and
oral antidiabetic drugs could be improved the diabetic
symptoms. Histologically pathological changes are seen
in sections of pancreas, liver and kidney. The numbers
of pancreatic islets are decreased and the cells of the
remaining islets are abnormal.
Other species with inherited diabetic symptoms
Sand rat
The sand rat (Psammomys obesus) lives in the desert
regions of North Africa and near east [99]. The animals
develop diabetic symptoms when fed chow instead of an
all vegetable diet. Within 2-3 months the diabetic syn-
drome in the sand rat usually develops. Severely hyper-
glycemic animals die prematurely from ketosis. Dubault
et al recommend sand rat (Psammomys obesus)a sa
model of latent IDDM in NIDDM patients [100].
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T h es p i n ym o u s e( Acomys cahirinus)i sf o u n di nt h e
semi-desert areas of the Eastern Mediterraneann [101].
Diabetes occurs in about 15% of the animals under
laboratory conditions. Diabetes is accompanied by
hyperplasia of the endocrine pancreas. Some animals
show obesity, mild hyperglycemia, and hyperinsulinemia
and some have frank hyperglycemia with glucosuria that
leads to fatal ketosis. All spiny mice characteristically
have massive hyperplasia of pancreatic islets and
increased pancreatic insulin content.
African hamster (Mystromys Albicaudatus)
Schmidt et al. described spontaneous diabetes mellitus
in South African hamsters (Mystromys albicaudatus)
[96]. Hyperglycemia, glucosuria, ketonuria, polyuria,
polyphagia, polydipsia and pancreatic lesions include b-
cell vacuolization, glycogen infiltration, nuclear pycnosis,
margination of organelles, and b-cell death are the char-
acteristics of the diabetic syndrome in this species.
TUCO-TUCO
Wise et al reported that the diabetic syndrome in Tuco-
tucos (Ctenomis talarum) is similar to that in sand rats
and spiny mice. However Tuco-tucos tend to have less
hyperglycemia and are less prone to ketosis [102]. Many
animals, mainly males, become hyperphagic. In few ani-
mals degranulation of b cell is the usual lesion in the
pancreas, but amyloid hyalinization of islets has been
observed.
MACACA NIGRA
Howard found a high incidence of spontaneous diabetes
mellitus in Macaca nigra (Celebes black apes) [103].
Diabetes mellitus signs include hyperglycemia, decreased
clearance of glucose, in intravenous tolerance tests,
reduced insulin secretion and increased serum lipids.
Atherosclerosis, thickened basement membranes of
muscle capillaries, and cataracts are the secondary mani-
festations of diabetes mellitus [104].
Transgenic Animals
Transgenic Mice
Transgenic mouse model of chronic hyperglycemia is
described by Schaefer et al [105]. The extracellular ligand
binding domain of the human insulin receptor can be
expressed as a stable soluble protein that is efficiently
secreted and binds insulin with high affinity. Expression
under the mouse transferrin promoter of a transgene
encoding a secreted derivative of the human insulin recep-
tor in transgenic mice results in the accumulation of this
high-affinity insulin-binding protein in the plasma. Altera-
tions of glucose homeostasis are induced including postab-
sorptive hyperglycemia concomitant with increased
hepatic glucose production and hyperinsulinemia. Palmiter
et al. developed a method of deleting specific cell lineages
that entailed microinjection into fertilized eggs of a
chimeric gene in which a cellspecific enhancer/promoter
is used to drive the expression of a toxic gene product
[106]. Microinjection of a construct in which the elastase I
promoter/enhancer is fused to a gene for diphtheria A
polypeptide resulted in birth of mice lacking a normal
pancreas because of the expression of the toxin in pan-
creatic acinar cells. A small pancreatic rudiment, contain-
ing islet and ductlike cells, was observed in some of the
transgenic mice. Aichele et al. used a synthetic peptide
corresponding to an immunodominant epitope of lympho-
cytic choriomeningitis virus glycoprotein (LCMV GP) to
prime or to tolerize CD8+ T cells in vivo [107]. Peptide-
specific tolerance was then examined in transgenic mice
expressing LCMV GP in the b islet cells of the pancreas.
These mice developed CD8+ T cell-mediated diabetes
within 8-14 days after LCMV infection.
Specific peptide-induced tolerance prevented autoim-
mune destruction of b islet cells and diabetes in this
transgenic mouse model. Oldstone et al. showed that
virus infection triggers insulin-dependent diabetes melli-
tus in a transgenic mouse model [108]. Ablation of tol-
erance and induction of diabetes by virus infection in
viral antigen transgenic mice was reported by Ohashi et
a l .[ 1 0 9 ] .V o nH e r r a t he ta l .i n v e s t i g a t e dh o wv i r u s
induces a rapid or slow onset insulin-dependent diabetes
mellitus in two distinct transgenic mouse models. Von
Herrath et al. evaluated the role of the costimulatory
molecule B7-1 in overcoming peripheral ignorance in
transgenic mice which expressed the glycoprotein or
nucleoprotein of lymphocytic choriomeningitis virus as
the self-antigen in pancreatic b-cells [110]. Von Herrath
and Holz reported that pathological changes in the islet
milieu precede infiltration of islets and destruction in b-
cells by autoreactive lymphocytes in a transgenic model
of virus-induced IDDM. RIP-LCMV transgenic mice
that express the viral glycoprotein or nucleoprotein
from lymphocytic choriomeningitis virus (LCMV) under
control of the rat insulin promoter (RIP) in pancreatic
b-cells develop autoimmune diabetes after infection with
LCMV [111]. Upregulation of MHC class II molecules
associated with the attraction/activation of antigen pre-
senting cells to the islets occurs as soon as 2 days after
LCMV inoculation of transgenic mice, clearly before
CD4+ and CD8+ lymphocytes are found entering the
cells. Moritani et al reported the prevention of adop-
tively transferred diabetes in non obese diabetic mice
with IL-10-transduced islet-specific Th1 lymphocytes as
a gene therapy model for autoimmune diabetes [112].
Miscellaneous Models
Invertebrate animal model
The invertebrate silk worm Bombyx mori is used for the
identification of anti-diabetic drugs in this model. The
silk worm fed a high-glucose diet (10% glucose
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lymph sugar level compared with silk worms fed a nor-
mal diet. The hemolymph sugar level increased
following intake of up to a 33% glucose diet without
saturation. The other parameters like body size and
weight was also influenced by this model.
The use of mammalian animals to screen for anti-dia-
betic drugs, however is not only very expensive from an
Table 1 Advantages and Disadvantages of different Models of Diabetes mellitus
S.
No
Methods Advantage Disadvantage
1
(a)
Pancreatectomy in
dogs
Resembles human type 2 diabetes due to
reduced islet beta cell mass
Avoids cytotoxic effects of chemical
diabetogens on other body organs
Involvement of cumbersome technical and post operative procedures
Occurrence of some other digestive problems (as a result of part of
excision of exocrine portion (deficiency of amylase enzyme)
Dissection of alpha islets (glucagon secreting cells) too along with beta
cells leading to problems in counter regulatory response to
hypoglycemia
Mortality is comparatively higher
1
(b)
Alloxan induced
diabetes
Selective loss of pancreatic beta cells
leaving other pancreatic alpha and delta
cells intact
Residual insulin secretion makes the
animals live long without insulin treatment
Ketosis and resulting mortality is relatively
less.
Comparatively cheaper, easier to develop
and maintain
Hyperglycemia develops primarily by direct cytotoxic action on the
beta cells and insulin deficiency rather than consequence of insulin
resistance
Less stable and reversible because of the spontaneous regeneration of
beta cells
May produce toxic effects on other body organs
Variability of results on development of hyperglycaemia is perhaps
high
1
(c)
Streptozotocin induced
diabetes
Diabetes induced by streptozotocin is more
stable
This model can be used for longer
experimental study
Comparatively costlier to develop
Mortality is relatively more
1
(d)
Hormone induced
diabetes
Stable and irreversible diabetes can be
induced
Ketonuria and ketonemia occurs
Not developed in small laboratory animals
Comparatively costlier to develop
May affect other organs
1
(e)
Virus induced diabetes Stable and irreversible diabetes can be
induced
Comparatively costlier to develop
It develops Type 1 diabetes Handling of virus requires a technical
expert
1
(f)
Other diabetogenic
compounds
Comparatively cheaper to develop
Mortality is relatively less
Can be developed in all type of
experimental animals
May affect other organs
Variability of results on development of hyperglycaemia is high
1
(g)
Insulin deficiency due
to insulin antibodies
State of insulin deficiency occurs
Induce a transient diabetic syndrome
Comparatively costlier to develop
Reversible at lower doses
Ketonemia, ketonuria, glucosuria, and acidosis occurs in higher dose
2
(a)
Spontaneously diabetic
rats
Hyperglycemia persists for several days A diabetes and obesity symptom overlaps
Not identical to those in human disease
2
(b)
Spontaneously diabetic
mice
Hyperlipidemia can be studied as lipid
contents increases
Polyphagia and polyuria occurs
2
(c)
Chinese hamsters Handling is comparatively difficult than rats
and mice
Ketonuria, polyuria, polyphagia, polydipsia occurs
2
(d)
Other species with
inherited diabetic
symptoms
Handling is comparatively difficult than rats
and mice
Comparatively costlier to develop
2
(e)
Transgenic animals In vivo effect of single gene or mutation on
diabetes can be studied
Dissection of complex genetics of type 2
diabetes become easier
Costly method
Experts are required
3
(a)
Invertebrate animal
model
Lesser time is required
No use of vertebrates
Comparatively cheaper
The physiology and anatomy matches less with humans
3
(b)
Diet Induced metabolic
dysregulation
Baboons and humans are genetically,
anatomically, and physiologically very similar
Cardiac complications can be studied
Handling of baboon is somewhat difficult
Veterinarian is required
Costly model
Kumar et al. Cardiovascular Diabetology 2012, 11:9
http://www.cardiab.com/content/11/1/9
Page 10 of 13animal husbandry perspective, but also prevents ethical
problems in terms of animal welfare. It is far less costly
to rear silkworms than mammals and a large number of
larvae can be maintained in a small space [113].
Diet Induced metabolic dysregulation
The model is clinically relevant for studying diet
induced metabolic dysregulation. In this model non-
human primates Baboon (Papio hamadryas sp.) is
induced with high sugar, high fat diet after 12 hour fast-
ing. The composition of diet includes 73% Purina Mon-
key Chow 5038 (a grain-based meal), 7% lard, 4%
Crisco, 4% coconut oil, 10.5% flavored high fructose
corn syrup, and 1.5% water. After 8 weeks of dietary
exposure increase in body fat and triglyceride concentra-
tion is observed along with change in percentage glyco-
sylated hemoglobin (HbA1c) and adipokines. The
baboons and humans are genetically, anatomically, and
physiologically very similar. Baboons and humans also
appear to develop similar metabolic disorders, earlier
studies have documented spontaneous obesity, insulin
resistance, and a form of adult-onset diabetes in captive
baboons [114].
Conclusion
The methods cited in the above review have some
advantages and disadvantages depicted in Table 1. How-
ever each and every newly synthesized drug goes into
the market and used in human beings until and unless
it studied on the laboratory animals. The characteristic
features of disease and pathological changes during dis-
ease in small animals (rats or mice) are near about simi-
lar to that of human beings. Thus the preclinical study
is always done before going to clinical study as human
life is more precious than that of animals. The use of
smaller animal models such as mice will also reduce the
cost of experiments for test compound. Further, the
selection of particular animal model is particularly
depending on the investigator’s choice whether to use
inbred or outbreed, availability of particular strain, aim
of scientific strategy, type of drug being sought, institu-
tional financial and facility resources in the type 2 dia-
betes research and pharmaceutical drug discovery and
development programme. The detailed investigations in
these diabetic animal species are urgently required for
better understanding of the disease mechanisms in
much closely similar human situation as well as for dis-
covering newer targets and drugs for the treatment of
type 2 diabetes.
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